**Core tip:** A prospective study conducted on 120 subjects divided into: Treatment naïve hepatitis C virus (HCV) patients, HCV patients treated with old standard of care, HCV associated with antinuclear antibody (ANA) and healthy control group. Teffs/Tregs imbalance was evaluated. Results showed that HCV patients exhibited significant higher levels of both Teffs and Tregs markers. Interferon-α and ribavirin therapy suppresses proliferation of Tregs. More significant suppression of Tregs was observed in HCV patients with autoantibodies favoring pathological autoimmune response. Teffs markers were significantly elevated in HCV treated group and in HCV group with ANA +ve in comparison to treatment naïve HCV group.

INTRODUCTION
============

Over 200 million people worldwide are suffering from chronic hepatitis C virus (HCV) infection and liver cirrhosis will be developed in about a quarter of these patients\[[@B1]\]. The prevalence rate of HCV genotype 4 in high risk populations in Egypt ranges from 73% to 90% and it was also found to be highly prevalent in sub-Saharan Africa and in the Middle East\[[@B2],[@B3]\].

T lymphocytes play a major role in cell mediated immunity\[[@B4],[@B5]\]. The several subsets of T cells have distinct functions and the majority is part of the adaptive immune system. Other subtypes can effectively present antigens to other T cells and are considered to be part of the innate immune system\[[@B6]\].

HCV is accompanied with different autoimmune manifestations\[[@B7]\], and could be a stimulator for the autoimmune reactions causing production of autoantibodies\[[@B8]\]. More recently, Acay et al\[[@B9]\] stated that the auto-antibodies in chronic HCV infection are highly incident. The authors stated that high percentages of patients with chronic hepatitis C had anti-mitochondrial antibodies, anti-smooth muscle antibodies, antinuclear antibody (ANA), thyroid antibody and anti-liver kidney microsomal antibodies.

The old HCV therapeutic protocol recommended by National Institutes of Health\[[@B10]\] was pegylated interferon (PEG-IFN) and ribavirin. Either endogenous or exogenous IFN-α leads to down regulation of CD4^+^ FoxP3^hi^IFN-γ^neg^ activated T regulatory cells (aTregs) while at the same time induces induction of of CD4^+^ FoxP3^low/neg^IFN-γ^pos^ T-activated cells (aTeffs). IFN-α play an essential role in suppression of Tregs *via* inhibition of interleukin-2 secretion\[[@B11]\].

Together, these observations support the fact that in early antiviral response there is a production of IFN-α which enhances CD4 effector functions by inhibiting Tregs activation, whereas sustained elevation of IFN-α reverses Tregs/Teffs balance towards Teffs activation, generation of auto antibody and development of autoimmunity.

The objective of the present study is to evaluate the extent of Teffs/Tregs imbalance in chronic HCV and its association with old standard of care as well as the presence of ANA.

MATERIALS AND METHODS
=====================

Study outcomes
--------------

Our research hypothesis was that HCV with or without IFN-α and ribavirin is usually associated with Tregs/Teffs imbalance with subsequent generation of autoantibodies.

The primary outcome for this study was to evaluate Teffs/Tregs balance and regulation in chronic HCV through assessment of Tregs markers (granzyme 2, CD69 and FoxP3), Teffs markers (TNFRSF4, INFγ) and *CD4*, *CD25* genes. Assessment of the effect of IFN-α and ribavirin on Teffs/Tregs balance as well as the association of Teffs/Tregs balance with the presence of antinuclear antibody were also conducted.

Study population
----------------

This was a prospective study conducted in Biochemistry and Molecular Biology Unit, Cairo University, Faculty of Medicine. The study included one hundred and twenty subjects categorized into 4 groups: Group I (30 patients) treatment naïve chronic HCV patients; Group II (30 patients) chronic HCV patients treated with the old standard of care therapy; Peg-IFN-α and ribavirin (Peg/Riba), group III (30 patients) chronic HCV patients associated with non-organ specific autoantibody and group IV, 30 healthy persons served as a control group. The patients attended the Internal Medicine Department at Beni-Sueif General Hospital. Healthy controls matched the age and sex of other patients. Cairo University Institutional review board in Faculty of Medicine approved the study. Informed written consent was signed by all subjects of the study.

The eligibility of selected patients included: (1) age between 18 and 65 years old; (2) anti-HCV positive serum; (3) positive HCV RNA detected by reverse-transcription/polymerase chain reaction (RT/PCR); (4) non-organ specific autoantibody by positive ANA test (titer \> 1/32) in group III only and \< 1/16 in all other groups; and (5) white blood cell \> 3.500/mm^3^.

A signed informed consent was got in accordance with Declaration of Helsinki ethics guidelines.

Exclusion criteria include patients with: Hepatocellular carcinoma, HBV co-infection, severe psychiatric disease, HIV-positive patients, co-morbid serious conditions, schistosomiasis mansoni, past history of alcohol abuse or long use of hepatotoxic drugs.

All HCV-infected patients in the treated group had a 48 wk course of old standard of care (Peg/Riba therapy) and achieved sustained virologic response. The T cells markers were analyzed after more than 6 mo of the end of the Peg/Riba course.

Study analytic procedure
------------------------

Whole blood was obtained from all subjects of the study. The mononuclear cell layer was isolated using Ficoll (Sigma, St. Louis, MO, United States) and centrifugation was conducted for 30 min at 400 g in cooling centrifuge.

**RNA extraction:** Total RNA was isolated from mononuclear cell layer using Qiagen purification reagent (Qiagen, CA, United States). The extracted RNA was quantified and checked for purity using a spectrophotometer (260/280 w.l.).

**Primer sequence:** PCR primers were got from GenBank RNA sequences cited at the following website: <http://www.ncbi.nlm.nih.gov/tools/primer-blast> (Table [1](#T1){ref-type="table"}).

###### 

Primers for *TNFRSF4(OX40)*, *granzyme 2*, *CD69*, *CD4*, *CD25*, *FoxP3* and *interferon* *γ* genes

  ------------------------- -----------------------------------------------
  *TNFRSF4OX 40*            Forward: ′5 GCA ATA GCT CGG ACG CAA TCT 3′
  DQ032625.1                Reverse: ′5 GAG GGT CCC TGT GAG GTT CT 3′
  *Granzyme 2*              Forward: ′5 TAC CAT TGA GTT GTG CGT GGG 3′
  NM_004131.4               Reverse: ′5 GCC ATT GTT TCG TCC ATA GGA GA 3′
  *CD69*                    Forward: ′5 GGT CAC CCA TGG AAG TGG TC 3′
  NM_001781.2               Reverse: ′5 GAC TTC GGA CCA CAG AGC AG 3′
  *CD4* NM_001195017.2      Forward: ′5 CTG CAA GTT CTC ACA CCG TC 3′
                            Reverse: ′5 CTA GAG TTG CCT GCT CTG CC 3′
  *CD25* IL2R NM_000417.2   Forward: ′5 GCT CTA CAC AGA GGT CCT GC 3′
                            Reverse: ′5 AGC ACA ACG GAT GTC TCC TG 3′
  *FoxP3*                   Forward: ′5 CCC ATC CCC AGG AGT CTT G 3′
  NG_007392.1               Reverse: ′5 ACC ATG ACT AGG GGC ACT GTA 3′
  *Interferon γ*            Forward: ′5 ATG GTT GTC CTG CCT GCA AT 3′
  NG_015840.1               Reverse: ′5 CTT GCT TAG GTT GGC TGC CT 3′
  ------------------------- -----------------------------------------------

**Real-time quantitative PCR using SYBR Green I:** Step One plus real-time PCR system was used in the analysis using software version 3.1 (Applied Biosystems, United States). Optimization of the annealing temperature was conducted for the PCR protocol and for the primer sets.

All cDNA were prepared for all gene markers, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and for non-template negative control.

Five microliter of total RNA was used to generate cDNA using 20 pmol antisense primer and 0.8 μL AMV reverse transcriptase at 37 °C for 60 min. The relative abundance of mRNA species was evaluated using the SYBR^®^ Green method (Applied Biosystems, CA, United States).

Annealing temperature of 60 °C was optimized for all primer sets. Real time polymerase reaction was performed in 25 μL reaction volume consisting of Mater Mix of SYBR Green, 3 μL of cDNA, 900 nmol/L of every primer. Amplification conditions were conducted according to the manufacturer specifications: 2 min at 50 °C, 10 min at 95 °C, 40 repeated cycles with 15 s denaturation and 10 min of annealing/extension at 60 °C.

Calculation of relative quantification (relative expression)
------------------------------------------------------------

The resulting data were expressed in Cycle threshold (Ct). The PCR data results show Ct values of all studied genes (*CD69, CD4, granzyme 2, TNFRSF4, FoxP3, CD25 and IFN*γ) and the house keeping gene (GAPDH). A negative control sample was no template cDNA was used. Target gene expression was related to GAPDH.

Data were calculated using the Applied Biosystems Step One plus software. Relative gene expressions of all assessed genes were calculated using the comparative Ct method. All values were normalized to GAPDH housekeeping gene and expressed as fold changes relative to the background levels found in the control samples.

Statistical analysis
--------------------

Statistical Package of Social Studies (SPSS) version 16.0.1 (SPSS Inc., Chicago, IL, United States) was utilized. Numerical data were presented as mean ± standard deviation. The null hypothesis was calculated for multiple groups by a single-factor ANOVA and for two groups by unpaired *t*-test. Statistically significant was considered if *P* value was \< 0.05.

RESULTS
=======

This study included 120 subjects divided into four groups. There weren't any difference between the four groups with statistical significance regarding age, sex distribution, albumin and T.bilirubin values (*P*-value \> 0.05).

Findings of the present study exhibited that chronic HCV patients exhibited significant higher levels of both Teffs and Tregs markers as compared to healthy control group. Tregs markers (granzyme 2, CD69, FoxP3) were significantly decreased in Peg/Riba treated HCV patients in comparison to treatment naïve HCV group (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

###### 

Relative gene expression of Tregs and Teffs specific genes in the four groups

                     **Group I (naïve)**   **Group II (Peg/Riba)**   **Group III (ANA+)**   **Group IV (control)**
  ------------------ --------------------- ------------------------- ---------------------- ------------------------
  Granzyme 2 Tregs   0.704 ± 0.039         0.603 ± 0.046             0.400 ± 0.042          0.489 ± 0.053
  CD69 Tregs         0.647 ± 0.037         0.54 ± 0.049              0.306 ± 0.036          0.383 ± 0.043
  FoxP3 Tregs        0.531 ± 0.033         0.444 ± 0.046             0.330 ± 0.039          0.39 ± 0.030
  TNFRSF4OX 40       0.596 ± 0.047         0.688 ± 0.057             0.707 ± 0.05           0.482 ± 0.056
  CD4                0.584 ± 0.034         0.677 ± 0.048             0.712 ± 0.042          0.528 ± 0.05
  CD25               0.595 ± 0.039         0.684 ± 0.053             0.73 ± 0.053           0.495 ± 0.041
  Interferon γ       0.466 ± 0.035         0.483 ± 0.035             0.522 ± 0.044          0.357 ± 0.038

ANA: Antinuclear antibody.

###### 

Multiple comparisons of gene expression of Tregs markers in the four studied groups

                      **Group I naïve**   **Group II Peg/Riba**   **Group III ANA+**   **Group IV control**
  ------------------- ------------------- ----------------------- -------------------- ----------------------
  FOX3                                                                                 
  Group I naïve                           ^a^*P* ≤ 0.05           ^d^*P* ≤ 0.001       ^b^*P* ≤ 0.01
  Group II Peg/Riba   ^a^*P* ≤ 0.05                               ^a^*P* ≤ 0.05        ^b^*P* ≤ 0.01
  Group III ANA+      ^d^*P* ≤ 0.001      ^a^*P* ≤ 0.05                                ^d^*P* ≤ 0.001
  Group IV control    ^b^*P* ≤ 0.01       ^b^*P* ≤ 0.01           ^d^*P* ≤ 0.001       
  CD69                                                                                 
  Group I naïve                           ^b^*P* ≤ 0.01           ^b^*P* ≤ 0.01        ^d^*P* ≤ 0.001
  Group II Peg/Riba   ^b^*P* ≤ 0.01                               ^b^*P* ≤ 0.01        ^d^*P* ≤ 0.001
  Group III ANA+      ^b^*P* ≤ 0.01       ^b^*P* ≤ 0.01                                ^d^*P* ≤ 0.001
  Group IV control    ^d^*P* ≤ 0.001      ^d^*P* ≤ 0.001          ^d^*P* ≤ 0.001       
  Granzyme                                                                             
  Group I naïve                           ^d^*P* ≤ 0.001          ^d^*P* ≤ 0.001       ^d^*P* ≤ 0.001
  Group II Peg/Riba   ^d^*P* ≤ 0.001                              ^b^*P* ≤ 0.01        ^d^*P* ≤ 0.001
  Group III ANA+      ^d^*P* ≤ 0.001      ^b^*P* ≤ 0.01                                ^d^*P* ≤ 0.001
  Group IV control    ^d^*P* ≤ 0.001      ^d^*P* ≤ 0.001          ^d^*P* ≤ 0.001       

ANA: Antinuclear antibody.

In HCV patients with autoantibodies, Tregs markers were significantly decreased in comparison to all the other studied groups (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

![Relative gene expression of Tregs specific genes in the studied groups. ^a^Significant difference *vs* control group; ^b^Significant difference *vs* treatment naïve HCV group; ^c^Significant difference *vs* HCV group after treatment. HCV: Hepatitis C virus; IFN: Interferon.](WJH-8-1287-g001){#F1}

Teffs specific genes (*TNFRSF4* and *IFN-*γ) and *CD4, CD25* showed significant elevation in treatment naïve HCV group in comparison to control group (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

![Relative gene expression of Teffs specific genes and CD4, CD25 in the studied groups. ^a^Significant difference *vs* control group; ^b^Significant difference *vs* treatment naïve HCV group. HCV: Hepatitis C virus.](WJH-8-1287-g002){#F2}

###### 

Multiple comparisons of gene expression of Teffs markers in the four studied groups

                      **Group I naïve**   **Group II Peg/Riba**   **Group III ANA+**   **Group IV control**
  ------------------- ------------------- ----------------------- -------------------- ----------------------
  TNFRSF4OX 40                                                                         
  Group I naïve                           ^b^*P* ≤ 0.01           ^a^*P* ≤ 0.05        ^a^*P* ≤ 0.05
  Group II Peg/Riba   ^b^*P* ≤ 0.01                               NS (*P* \> 0.05)     ^b^*P* ≤ 0.01
  Group III ANA+      ^a^*P* ≤ 0.05       NS (*P* \> 0.05)                             ^d^*P* ≤ 0.001
  Group IV control    ^a^*P* ≤ 0.05       ^b^*P* ≤ 0.01           ^d^*P* ≤ 0.001       
  CD4                                                                                  
  Group I naïve                           ^b^*P* ≤ 0.01           ^a^*P* ≤ 0.05        ^a^*P* ≤ 0.05
  Group II Peg/Riba   ^b^*P* ≤ 0.01                               NS (*P* \> 0.05)     ^a^*P* ≤ 0.05
  Group III ANA+      ^a^*P* ≤ 0.05       NS (*P* \> 0.05)                             ^b^*P* ≤ 0.01
  Group IV control    ^a^*P* ≤ 0.05       ^a^*P* ≤ 0.05           ^b^*P* ≤ 0.01        
  CD25                                                                                 
  Group I naïve                           ^b^*P* ≤ 0.01           ^a^*P* ≤ 0.05        ^a^*P* ≤ 0.05
  Group II Peg/Riba   ^b^*P* ≤ 0.01                               NS (*P* \> 0.05)     ^b^*P* ≤ 0.01
  Group III ANA+      ^a^*P* ≤ 0.05       NS (*P* \> 0.05)                             ^d^*P* ≤ 0.001
  Group IV control    ^a^*P* ≤ 0.05       ^b^*P* ≤ 0.01           ^d^*P* ≤ 0.001       
  Interferon-γ                                                                         
  Group I naïve                           ^b^*P* ≤ 0.001          ^b^*P* ≤ 0.001       ^a^*P* ≤ 0.05
  Group II Peg/Riba   ^b^*P* ≤ 0.001                              NS (*P* \> 0.05)     ^a^*P* ≤ 0.05
  Group III ANA+      ^b^*P* ≤ 0.001      NS (*P* \> 0.05)                             ^b^*P* ≤ 0.01
  Group IV control    ^a^*P* ≤ 0.05       ^a^*P* ≤ 0.05           ^b^*P* ≤ 0.01        

ANA: Antinuclear antibody; NS: Non significant.

More significant elevation in *Teffs* genes was observed in both Peg/Riba treated HCV and HCV with autoantibodies groups as compared to treatment naïve HCV and control groups (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

DISCUSSION
==========

HCV is reported to suppress immune system to sustain chronic infection. Accumulation of Tregs and activation of inhibitory signaling pathways play essential roles in suppressing antiviral effector T cells (Teffs). The mechanisms by which HCV impairs Teffs include: Induction of Tregs, Th1 deficiency or Th2 dominance, blunted T cell activation, T cell apoptosis and T cell anergy\[[@B12]\].

The objectives of the present study were to assess the extent of upregulation of Tregs in HCV patients whether or not associated with auto-antibodies. In the present study, we have evaluated certain markers of Tregs and Teffs in peripheral blood mononuclear cells.

FOXP3 (forkhead box P3) is a member of forkhead/winged-helix family of transcriptional regulators which are master regulators in the development and function of Tregs\[[@B13],[@B14]\].

Our results exhibited significant upregulation of FOXP3 in all HCV patients groups as compared to healthy controls. Other studies also confirmed accumulation of FOXP3^+^ Tregs in most chronic viral infections with subsequent suppression of antiviral CD4^+^ and CD8^+^ T cell responses\[[@B15]-[@B18]\].

Moreover, findings of our study demonstrated more significant decrease in Tregs specific genes (*CD69*, *FoxP3*, and *granzyme 2*) in HCV patients group after Peg/Riba therapy. Similar findings were reported by Langhans et al\[[@B19]\] who stated that ribavirin can inhibit functions of HCV-specific Tregs beside its immuno-stimulatory effects on TH1 cells. Ribavirin can subsequently inhibit Treg-mediated suppression of Teffs in chronic HCV infections pushing the disease towards autoimmune responses.

Golding et al\[[@B11]\] stated that IFN-α, promotes proliferation of FoxP3^Low/Neg^IFN-γ^Pos^ activated Teffs while simultaneously suppresses the development of FoxP3^HI^IFN-γ^Neg^ activated Tregs. These data coincided with our findings in group II in relation to the other groups.

*CD4* gene product is a membrane glycoprotein of T lymphocytes that mediates initiation and augments early phase of T-cell activation\[[@B20]-[@B22]\]. Findings of the present study demonstrated significant elevation of *CD4* gene in all HCV groups in comparison to control group suggesting increase in activated T cells function. More significant elevation of CD4 was observed in HCV after treatment and in HCV with auto-antibodies groups.

CD25 is a type I transmembrane protein present on activated T cells, activated B cells and in memory CD8 T cells\[[@B23]-[@B27]\]. Our results demonstrated significant elevation of CD25 in all HCV studied groups with more significant elevation after Peg/Riba therapy. Similar findings were reported by Caetano et al\[[@B28]\] in chronic HCV patients during Peg/Riba treatment who presented an amplified CD8 T-cell responses specific to HCV and more increase Teffs.

Moorman et al\[[@B12]\] showed that many inhibitory signaling pathways were up-regulated during chronic HCV infection, resulting in expansion of Tregs and contraction of Teffs. Thus, this inhibitory pathway may not only regulate proliferation and differentiation of naïve T cells, but also control responses of Teffs, memory cells, and expansion of Tregs\[[@B29]\].

These facts coincided with our results that showed significant elevation of Tregs specific genes (*CD69*, *FoxP3*, and *granzyme 2*) and significant elevation of Teffs specific genes (*TNFRSF4*, *INF-*γ) and *CD4*, *CD25* genes in both groups of HCV whether naïve or after treatment in comparison to healthy controls.

Granzyme B encodes a protein that is essential in induction of cell-mediated immune response for the faster initiation of target cell apoptosis by cytolytic T lymphocytes\[[@B30]\]. Tregs possess granzyme B, enabling them to induce apoptosis in effector T-cells\[[@B31],[@B32]\]. Our results demonstrated that granzyme B was found to be significantly elevated in naïve HCV patients with significant decrease after Peg/Riba therapy. More significant decrease in its levels was observed in HCV patients with autoantibodies favoring autoimmune response in those patients.

CD69 expression was studied by Colbeck et al\[[@B33]\] and they stated that Tregs expressing CD69(+) are more proliferative and more suppressive than their CD69(-) counterparts. This finding explains our results that showed significant lower CD69 expression in HCV patients with autoantibodies suggesting inhibition of Tregs activity favoring autoimmune environment.

IFN-γ is a member of the type II class of interferons\[[@B34]\]. Longhi et al\[[@B31]\] stated that CD8^+^ T cells when cultured on their own secrete much higher levels of IFN-γ in patients with autoimmune hepatitis when compared to normal subjects and have a high proliferation rate. This finding coincided with our results that demonstrated significant higher levels of IFN-γ in patients with autoantibodies than healthy controls.

The protein encoded by the *TNFRSF4* gene belongs to tumor necrosis factor - receptor superfamily that has essential roles in CD4^+^ T cell response\[[@B35],[@B36]\].

Our findings showed that, in HCV patients with ANA +ve, *TNFRSF4* and *IFN-*γ (T effector gene) were significantly higher as compared to HCV naïve and healthy control groups. This means that T effector cells dominate over T regulatory cells favoring autoimmunity and initiating pathological immune response with production of autoantibodies. Similar findings were reported by González-Amaro et al\[[@B37]\].

Also, our results agreed with similar findings reported by Longhi et al\[[@B31]\] who stated that regulatory T cells are decreased numerically and impaired functionally in autoimmune hepatitis. Similar to our results, several studies reported that HCV infection induces a dramatic increase in Tregs, which contributes to the immune response failure during HCV infection\[[@B38]\].

In conclusion, chronic HCV patients exhibited significant higher levels of both Teffs and Tregs in comparison to healthy controls. Moreover, elevated levels of Treg cells in patients with chronic HCV dampen both the CD4^+^ and CD8^+^ autologous T cell immune response. IFN-α and ribavirin therapy suppress proliferation of Tregs and do not restore the Teffs/Tregs imbalance. More significant suppression of Tregs was observed in HCV patients with autoantibodies favoring pathological autoimmune response.

COMMENTS
========

Background
----------

Hepatitis C virus (HCV) is accompanied with different autoimmune manifestations, and could be a stimulator for the autoimmune reactions causing production of autoantibodies. More recently, Acay et al stated that the auto-antibodies in chronic HCV infection are highly incident. The authors stated that high percentages of patients with chronic hepatitis C had anti-mitochondrial antibodies (AMA), anti-smooth muscle antibodies (ASMA), anti-nuclear antibodies (ANA), thyroid antibody and anti-liver kidney microsomal antibodies (anti-LKM-1). The old HCV therapeutic protocol was pegylated interferon (IFN) and ribavirin. IFN-α leads to down regulation of CD4^+^ FoxP3^hi^IFN-γ^neg^ activated T regulatory cells (aTregs) while at the same time induces induction of of CD4^+^ FoxP3^low/neg^IFN-γ^pos^ T-activated cells (aTeffs). Together, these observations support the fact that sustained elevation of IFN-α reverses Tregs/Teffs balance towards Teffs activation, generation of auto antibody and development of autoimmunity. The objective of the present study is to evaluate the extent of Teffs/Tregs imbalance in chronic HCV and its association with old standard of care as well as the presence of ANA.

Research frontiers
------------------

IFN-α/ribavirin old therapeutic protocol enhances CD4 effector (Teffs) functions by inhibiting Tregs activation. The old protocol reverses Tregs/Teffs balance towards Teffs activation, generation of auto antibody and development of autoimmunity.

Innovations and breakthroughs
-----------------------------

New direct acting antiviral drugs do not induce Tregs/Teffs imbalance, whereas the old standard of care IFN-α and ribavirin induce Tregs/Teffs imbalance. Replacing the old therapeutic protocol by the new direct acting antiviral drugs is mandatory because beside its efficacy, the new direct acting antiviral drugs do not induce autoimmunity.

Applications
------------

Chronic HCV patients exhibited significant higher levels of both Teffs and Tregs in comparison to healthy controls. Moreover, elevated levels of Treg cells in patients with chronic HCV dampen both the CD4^+^ and CD8^+^ autologous T cell immune response. IFN-α and ribavirin therapy suppress proliferation of Tregs and do not restore the Teffs/Tregs imbalance. More significant suppression of Tregs was observed in HCV patients with autoantibodies favoring pathological autoimmune response. Repalcing the old therapeutic protocol; IFN-α and ribavirin by the new direct acting antiviral drugs is mandatory and is also essential avoid Teffs/Tregs imbalance.

Terminology
-----------

Tregs also known as suppressor T cells, are a subpopulation of T cells that down-regulates or suppress induction, proliferation and activation of effector T cells. Tregs also maintain tolerance to self-antigens and prevent autoimmunity. Teffs includes various T cell types that actively respond to antigenic stimuli, such as co-stimulation. This includes helper T cells, cytotoxic or killer T cells, and potentially other T cell types as memory cells. HCV-induced autoantibodies involves: AMA, ASMA, ANA, thyroid antibody and anti-LKM-1. Forkhead box P3 is a member of forkhead/winged-helix transcriptional regulators which master the development and function of Tregs. *CD4* gene product is a membrane glycoprotein of T lymphocytes that mediates initiation and augments early phase of T-cell activation. Granzyme B is a protein that enables Tregs to induce apoptosis in effector T-cells. *TNFRSF4* gene belongs to tumor necrosis factor -receptor superfamily that plays essential roles in CD4^+^ T cell response.
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